John Braun Repeatedly Voted Against Efforts To Make Prescription Drugs And Health Care More Affordable
2022: Braun Voted Against Creating A Prescription Drug Affordability Board
2022: Braun Voted Against S.B. 5532, Which Created A Prescription Drug Affordability Board
2022: Braun Voted Against S.B. 5532, A Bill “Establishing A Prescription Drug Affordability Board.” In March 2022, Braun voted against: “AN ACT Relating to establishing a prescription drug affordability board.” The bill passed the Senate by a vote of 28-20 and was signed into law. [Washington State Legislature, S.B. 5532, 3/7/22]
- The Prescription Drug Affordability Board Identified The Need For Upper Limits On Drug Prices And Imposed Penalties On Increased Revenue For Some Prescriptions. “Senate Bill 5532 would establish the Prescription Affordability Board, said Sen. Karen Keiser, D-Des Moines. She advanced similar legislation to the governor’s desk in 2020, but it was vetoed when the pandemic ramped up and the legislature scrambled to respond. The board would identify prescription drug prices above a certain threshold and determine whether upper payment limits are needed. The bill requires the Department of Revenue to impose penalties on increased revenue for some prescriptions.” [Columbia Basin Herald, 1/20/22]
Washington’s Prescription Drug Affordability Board Aimed To Set Limits On What Individuals, State Agencies, And Insurers Must Pay For Prescription Drugs
AARP: S.B. 5532 “Would Create A Prescription Drug Affordability Board To Evaluate Prices And Set Limits On What Individuals, State Agencies, And Insurers Must Pay.” “AARP applauds Senator Karen Keiser (D–Des Moines) for introducing a bill to help protect Washington consumers from exorbitant price increases for prescription drugs. Senate Bill 5532 would create a Prescription Drug Affordability Board to evaluate prices and set limits on what individuals, state agencies, and insurers must pay. This legislation could lead to lower insurance premiums, reduce taxpayer spending on healthcare, and would help ensure people can afford the medication they need.” [AARP, accessed 12/9/25]
Prescription Drug Affordability Boards Were Considered “Necessary To Lower The Total Cost Of The Drugs For Payers” And Were Opposed By The Pharmaceutical Industry
National Academy For State Health Policy: Prescription Drug Affordability Boards Were “Necessary To Lower The Total Cost Of The Drugs For Payers.” “On March 24, 2022, Washington state joined five other leading states in establishing a Prescription Drug Affordability Board (PDAB) when Governor Inslee signed SB 5532, sponsored by Senator Karen Keiser, into law. Washington’s PDAB, like those already established in Maryland and Colorado, has the authority to limit what payers in the state will pay for certain high-cost drugs following an affordability review…More than a dozen states have enacted legislation to cap out-of-pocket costs for insulin and on March 30, 2022, the House passed a federal out-of-pocket cap for insulin at $35 a month (HR 6833). While out-of-pocket caps bring necessary and immediate relief to consumers, additional measures like a state PDAB or federal drug price negotiations, are also necessary to lower the total cost of the drugs for payers.” [National Academy for State Health Policy, 4/7/22]
PhRMA Described Prescription Drug Affordability Boards As “Government Price Setting Schemes” That “[Wedged] Government-Appointed Bureaucrats Between Doctors And Their Patients”
PhRMA Said Prescription Drug Affordability Boards Were “Government Price Setting Schemes That Let Politicians Set Medicine Prices With Little Accountability To, Or Input From, Patients And Their Doctors.” “Risk patients’ access to medicines. Prescription drug boards are government price setting schemes that let politicians set medicine prices with little accountability to, or input from, patients and their doctors. Under this scheme, an unelected board of bureaucrats evaluates the price of medicines and determines whether certain medicines and treatments are worth paying for, with the state coming between patients and the treatments their doctors prescribe.” [PhRMA, 10/10/23]
PhRMA Opposed Prescription Drug Affordability Boards And Claimed The Boards “[Wedged] Government-Appointed Bureaucrats Between Doctors And Their Patients.” “Groups motivated by special interests (see NASHP) and backed by insurance companies (see AARP) are pushing states to adopt flawed price-setting schemes, often in the form of prescription drug affordability boards (PDABs). Establishing these boards wedges government-appointed bureaucrats between doctors and their patients while shortsightedly focusing on only one component of health care — all too curiously avoiding any review of or actions on abusive health insurance practices. This is not good news for patients.” [PhRMA, 10/10/23]
2021: Braun Voted Against Increasing Washingtonians’ Access To More Affordable, Generic Prescription Drug Options, Including Insulin
April 2021: Braun Voted Against S.B. 5203, A Bill “Producing, Distributing, And Purchasing Generic Prescription Drugs.” In April 2021, Braun voted against S.B. 5203, a bill “producing, distributing, and purchasing generic prescription drugs.” The bill passed by a vote of 28-21. [Washington State Legislature, S.B. 5202, 4/21/21]
- S.B. 5203 Allowed Washington State To Distribute And Manufacture Generic Prescription Drugs By Forming Partnerships With Other States, Local Governments, Nonprofit Organizations, For-Profit Insurers And Medical-Care Providers. “Legislation that passed the state Senate on Thursday would enable Washington to not just buy generics, but also distribute and even manufacture the cheaper drugs. To do this, the state could form partnerships with a range of organizations: other states, local governments, nonprofit organizations, for-profit insurers and medical-care providers… This legislative session’s prescription drug bill, Senate Bill 5203, is the latest entry in the playbook as Olympia tries to bend the curve on drug costs.” [Cascade PBS, 3/4/21]
- Cascade PBS: S.B. 5203 Allowed “Washington State To Partner With Other States, Organizations And Companies To Procure Nonpatented Drugs, Often Generics.” “Having passed the Senate on a vote of 28-21, SB 5203 would enable Washington to enter the generic drug market more vigorously. The bill is driven partly by California’s push to begin manufacturing insulin and other drugs that are inexpensive to produce but have crept — or leapt — up in price. If enacted, the bill would allow Washington state to partner with other states, organizations and companies to procure nonpatented drugs, often generics. The group could contract with manufacturers, buy in bulk at reduced cost or make the drugs themselves.” [Cascade PBS, 3/4/21]
2019: Braun Voted Against Creating A Centralized Insulin-Purchasing Program To Allow Washington State To Purchase Insulin At Bulk Discount Rates
2019: Braun Voted Against S.B. 6113, A Bill “Creating A Central Insulin Purchasing Program.” In April 2019, Braun voted against S.B. 6113, a bill “creating a central insulin purchasing program.” The bill passed by vote of 28-20. [Washington State Legislature, S.B. 6113, 2/18/19]
- S.B. 6113 Would Create A Centralized Insulin-Purchasing Program, Allowing Washington State To Purchase Insulin At Bulk Discount Rates. “Senate Bill 6113: Modeled after the state’s decades-old Childhood Vaccine Program, a centralized purchasing program that takes advantage of ‘bulk discount rates,’ this bill would create a centralized insulin-purchasing program. Advocates hope the program could leverage the buying power of the state to drive down costs, but have urged lawmakers to include type I diabetics to the list of stakeholders involved in devising the purchasing strategy.” [Seattle Times, 2/19/20]
- Advocates Of S.B. 6113 Said S.B. 6113 Would Leverage The Buying Power Of The State To Drive Down Prescription Drug Costs. “Senate Bill 6113: Modeled after the state’s decades-old Childhood Vaccine Program, a centralized purchasing program that takes advantage of ‘bulk discount rates,’ this bill would create a
centralized insulin-purchasing program. Advocates hope the program could leverage the buying power of the state to drive down costs, but have urged lawmakers to include type I diabetics to the list of stakeholders involved in devising the purchasing strategy.” [Seattle Times, 2/19/20]
Braun Voted Against Requiring Health Insurance Companies To Cover Pre-Existing Conditions, Limit Out-Of-Pocket Expenses, Eliminate Lifetime Limits On Health Care Benefits, And Other Key Protections Of The Affordable Care Act
March 2019: Braun Voted Against H.B. 1870, A Bill “Making State Law Consistent With Selected Federal Consumer Protections In The Patient Protection And Affordable Care Act.” In March 2019, Baun voted against: “AN ACT Relating to making state law consistent with selected federal consumer protections in the patient protection and affordable care act.” The bill passed by a vote of 28-17. [Washington State Legislature, H.B. 1870, 3/27/19]
- H.B. 1870 Made Washington State Law Consistent With Federal Consumer Protections In The ACA, Including Requiring Insurance Plans Sold In Washington To Cover Pre-Existing Conditions, Limit Out-Of-Pocket Expenses, And Eliminate Lifetime Limits On Health Care Benefits Paid By Insurers. “Makes state law consistent with selected federal consumer protections in the Patient Protection and Affordable Care Act. Passed the Senate on March 27 by a vote of 28-17, four members excused. Bailey and Wagner voted no. This measure would make a number of provisions mandated by the federal ACA part of state law. Under HB 1870, Washington insurance plans would have to offer policies that cover pre-existing conditions, provide a wide range of benefits, limit out-of-pocket expenses a covered person must pay, and eliminate lifetime limits on health care benefits paid by insurers, and other mandates under the fACA, often referred to as Obamacare.” [Stanwood Camano News, 4/1/19]